Cite
HARVARD Citation
Gousis, C. et al. (2022). Beyond First Line CDK4/6 Inhibitors (CDK4/6i) and Aromatase Inhibitors (AI) in Patients with Oestrogen Receptor Positive Metastatic Breast Cancer (ER+ MBC): The Guy's Cancer Centre Experience. Clinical oncology. 34 (4), pp. e178-. [Online].